Literature DB >> 15736114

The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings.

Jennifer L Jenner1, Leo J Seman, John S Millar, Stefania Lamon-Fava, Francine K Welty, Gregory G Dolnikowski, Santica M Marcovina, Alice H Lichtenstein, P Hugh R Barrett, Carl deLuca, Ernst J Schaefer.   

Abstract

The metabolism of apolipoproteins (apo) (a) and B-100 within plasma lipoprotein (a) [Lp(a)] was examined in the fed state in 23 subjects aged 41 to 79 years who received a primed-constant infusion of [5,5,5-2H3] leucine over 15 hours. Lipoprotein (a) was isolated from the whole plasma using a lectin affinity-based method. Apolipoprotein (a) and apoB-100 were separated by gel electrophoresis, and tracer enrichment of each apolipoprotein was measured using gas chromatography/mass spectrometry. Data were fit to a multicompartmental model to determine fractional catabolic rates (FCRs) and secretion rates (SRs). The FCRs of apo(a) and apoB-100 (mean +/- SEM) within plasma Lp(a) were significantly different (0.220 +/- 0.030 pool/d and 0.416 +/- 0.040 pool/d, respectively; P < .001). Apolipoprotein (a) SR (0.50 +/- 0.08 mg/[kg per d]) was significantly lower than that of apoB-100 SR (1.53 +/- 0.22 mg/[kg per d]; P < .001) of Lp(a). Plasma concentrations of Lp(a) were correlated significantly with both apo(a) SR and apoB-100 SR (r = 0.837 and r = 0.789, respectively; P < .001) and negatively with apo(a) FCR and Lp(a) apoB-100 FCR (r = -0.547 and r = -0.717, respectively; P < .01). These data implicate different metabolic fates for apo(a) and apoB-100 within Lp(a) in the fed state. We therefore hypothesize that apo(a) does not remain covalently linked to a single apoB-100 lipoprotein but that it rather reassociates at least once with another apoB-100 particle, probably newly synthesized, during its plasma metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15736114     DOI: 10.1016/j.metabol.2004.10.001

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

Review 1.  Lipoprotein apheresis to treat elevated lipoprotein (a).

Authors:  Elisa Waldmann; Klaus G Parhofer
Journal:  J Lipid Res       Date:  2016-02-17       Impact factor: 5.922

2.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

3.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

4.  Enigmatic role of lipoprotein(a) in cardiovascular disease.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Lars Berglund
Journal:  Clin Transl Sci       Date:  2010-12       Impact factor: 4.689

5.  Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.

Authors:  Stefania Lamon-Fava; Santica M Marcovina; John J Albers; Hal Kennedy; Carl Deluca; Charles C White; L Adrienne Cupples; Judith R McNamara; Leo J Seman; Vanina Bongard; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2011-04-07       Impact factor: 5.922

6.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

Review 7.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

8.  Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry.

Authors:  Haihong Zhou; Jose Castro-Perez; Michael E Lassman; Tiffany Thomas; Wenyu Li; Theresa McLaughlin; Xie Dan; Patricia Jumes; John A Wagner; David E Gutstein; Brian K Hubbard; Daniel J Rader; John S Millar; Henry N Ginsberg; Gissette Reyes-Soffer; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  Rapid Commun Mass Spectrom       Date:  2013-06-30       Impact factor: 2.419

9.  Scavenger receptor-BI is a receptor for lipoprotein(a).

Authors:  Xiao-Ping Yang; Marcelo J Amar; Boris Vaisman; Alexander V Bocharov; Tatyana G Vishnyakova; Lita A Freeman; Roger J Kurlander; Amy P Patterson; Lewis C Becker; Alan T Remaley
Journal:  J Lipid Res       Date:  2013-06-29       Impact factor: 5.922

10.  Effects of renal replacement therapy on plasma lipoprotein(a) levels.

Authors:  Sylvia Rosas; Marshall Joffe; Megan Wolfe; Kenneth Brayman; Daniel J Rader
Journal:  Am J Nephrol       Date:  2007-12-05       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.